RxDoctor Payments Data

Conrad Miller, MD

Family Medicine · Macon, GANPI 1629149430

Payments from drug & device makers

$1,417in general payments, 2019–2025

Across 29 payments — averaging $48.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$766
  • AstraZeneca$252
  • Lilly USA, LLC$105
  • Astellas Pharma US Inc$100
  • Pfizer$68
  • Boehringer Ingelheim$63
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$1,31893%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk9$766
AstraZeneca3$252
Lilly USA, LLC6$105
Astellas Pharma US Inc1$100
Pfizer3$68
Boehringer Ingelheim3$63
Linus Health, Inc.1$24
Merck1$16
Amgen1$12
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,417 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$43,176
Medicare patients
54
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$105,119
MyrbetriqMirabegron28$24,490
FarxigaDapagliflozin Propanediol22$19,170
XareltoRivaroxaban12$16,466
JanuviaSitagliptin Phosphate19$13,326
EntrestoSacubitril/Valsartan11$10,432
EliquisApixaban13$7,640
GlyxambiEmpagliflozin/Linagliptin11$6,725
LinzessLinaclotide11$6,437
SymbicortBudesonide/Formoterol Fumarate23$5,245
Atorvastatin Calcium328$2,039
Tramadol Hcl144$1,946
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$1,720
Albuterol Sulfate HfaAlbuterol Sulfate89$1,708
Rosuvastatin Calcium252$1,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$63$111,844136 claims
Astellas Pharma US IncMyrbetriq$100$24,49028 claims
AstraZenecaFarxiga, Symbicort$252$24,41545 claims
MerckJanuvia$16$13,32619 claims
PfizerEliquis$68$7,64013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →